News

Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany. Developed by Abcam…
Read More...

Adamis Pharmaceuticals Corporation announced that it has entered into an exclusive distribution and commercialization agreement with Sandoz, a division of the Novartis Group, to…
Read More...

Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a…
Read More...

Agilent Technologies announced that it has entered into a definitive agreement to acquire privately-held ProZyme, Inc., a leading provider of glycan analysis reagents, kits and…
Read More...

OWC Pharmaceutical Research Corp. announced a successful completion of the first part of its Phase I, placebo controlled, maximal dose study to determine the safety and tolerability of…
Read More...

Akebia Therapeutics and Keryx Biopharmaceuticals announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger…
Read More...

The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new…
Read More...

Kite, a Gilead Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s…
Read More...

Pfizer Inc. announced that the European Commission (EC) has approved XELJANZ (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of…
Read More...

Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi's European generics business, by Advent and the companies have signed a Share Purchase…
Read More...

Purdue Pharma announced successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies for…
Read More...

RedHill Biopharma Ltd. announced that it has entered into a co-promotion agreement with Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel…
Read More...

Novaliq GmbH announced that NovaTears, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia. Dry eye is a…
Read More...

AbbVie and Calibr announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie's oncology research to…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for baloxavir marboxil as a single-dose, oral…
Read More...

Aquinox Pharmaceuticals announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain…
Read More...

The center will be based around LUMICKS' C-Trap optical tweezers-fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular…
Read More...

In the quest to develop a drug to effectively treat aggressive prostate cancer, NucleoBio Inc. has demonstrated efficacy for its newest product, Prostreat. Prostreat outperforms…
Read More...

Starpharma and Mundipharma today announced they have signed a licence agreement for the sales and marketing rights to VivaGel BV for 43 countries in Europe, Russia, the Commonwealth of…
Read More...

AbbVie and Calico announced an extension of their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including…
Read More...